暖暖视频免费高清视频中国在线观看,依依成人精品视频在线观看,精品少妇人妻AV一区二区,成人无码精品一区二区在线

One more step in Kexing Biopharm's R&D!

On the evening of August 14, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Human Interferon α2b Spray" was accepted.

Basic Information of the Drug for Registration

1.  Product Name: Human Interferon α2b Spray
2. Application Item: clinical trial for registration of drugs produced in China
3. Acceptance No.: CXSL2200374G
4. Indication: It is proposed for the treatment of initial or recurrent skin herpes simplex (oral herpes and genital herpes) caused by virus.
5. Dosage Form: spray

The promotion of the R&D of Human Interferon α2b Spray will help the Company further optimize the product portfolio, enrich the product pipelines, enhance the overall R&D capability, and build up the long-term profitability.

About Human Interferon α2b Spray
Human Interferon α2b Spray is a Class 2 modified new drug, independently developed by the Company, with optimized dosage form and administration route compared with the drugs already on the market. It has the obvious clinical advantages of increased drug concentration at the lesions through targeted local administration, convenient use and carrying, and good patient compliance. The Human Interferon α2b Spray is indicated for the treatment of initial or recurrent skin herpes simplex (oral herpes and genital herpes) caused by virus.